Revolution Medicines Posts $644M Q2 Loss, FDA Accepts Daraxonrasib NDA
RVMD has more than doubled off its 52-week low of $34.
Summary
Revolution Medicines reported a steep Q2 net loss of $644M, or $3.06 per share, driven by a $151M non-cash warrant charge and zero revenue. The loss widens significantly from the prior year, though the company holds $3.9B in cash and investments with $1.5B in royalty funding remaining. In a positive development, the FDA accepted the NDA for daraxonrasib following strong Phase 3 pancreatic cancer data, and the company is preparing for a U.S. launch while undergoing EMA review. Analysts raised price targets to a $201–$240 range, reflecting confidence in the drug's commercial prospects. The cash position provides runway, but the accelerating burn rate and lack of near-term revenue keep pressure on the stock.
At the time of this announcement, RVMD was trading at $207.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44B. The 52-week trading range was $34.00 to $205.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.